Search

Mark R Parthun

from Hilliard, OH
Age ~62
Get Report
Also known as:
Mark K Parthun
Phone and address:
5659 Cowall Ct, Hilliard, OH 43026
(614) 529-8873
Related to:
James Edward Parthun, 37James ParthunBruno C Ammon, 90Jonathan Parthun, 30Karen E Ammon, 60Ingeborg C Ammon, 89Matt Sean Parthun, 30Susan C Parthun, 64Lois J Parthun, 97Jeffrey T Parthun, 64Yvonne N Janvrin, 62Matthew Parthun, 30
Connected to:
Gregory R Parthum, 46Kindle J Partica, 48Adela Partida, 50Albertina Partida, 51Alec G Partida, 29Amario Partida, 40Andrea G Partida, 55Arbraham Partida, 42Ariann Partida, 37Chacon M Partida, 50

Mark Parthun Phones & Addresses

  • 5659 Cowall Ct, Hilliard, OH 43026 (614) 529-8873
  • 8719 Carter Rd, Hilliard, OH 43026 (614) 530-9546
  • Bothell, WA
  • Ionia, MI
  • Wheeling, WV
  • Darien, IL
  • Bloomington, IN
  • Chicago, IL
  • Downers Grove, IL
  • 5659 Cowall Ct, Hilliard, OH 43026

Work

Company: The ohio state university 2014 Position: Professor and chair

Education

Degree: Doctorates, Doctor of Philosophy Specialities: Biochemistry

Emails

m***[email protected]

Industries

Higher Education

Resumes

Resumes

Mark Parthun Photo 1

Professor And Chair

View page
Location:
Hilliard, OH
Industry:
Higher Education
Work:
The Ohio State University
Professor and Chair
The Ohio State University
Professor

Publications

Us Patents

Treatment Of Patients With Chronic Lymphocytic Leukemia

View page
US Patent:
6841565, Jan 11, 2005
Filed:
Mar 31, 2003
Appl. No.:
10/403667
Inventors:
David M. Lucas - Hilliard OH, US
Mark R. Parthun - Hilliard OH, US
John C. Byrd - Columbus OH, US
Michael R. Grever - Columbus OH, US
Assignee:
The Ohio State University - Columbus OH
International Classification:
A61K 3144
US Classification:
514346, 514352, 514357
Abstract:
The invention provides methods for treating a patient with chronic lymphocytic leukemia of B cells (B-CLL). One method comprises administering to a patient with B-CLL, one or more benzamide derivatives, the benzamide derivatives including MS-275 and related compounds. Another method comprises administering to a patient with B-CLL, one or more of the benzamide derivatives, and additionally administering to the patient one or more antibodies immunospecific for 1D10 antigen. Additional methods for inducing apoptosis of B-CLL cells and for increasing expression of 1D10 antigen in B-CLL cells using the benzamide derivatives are also provided.
Control profile
Mark R Parthun from Hilliard, OH, age ~62 Get Report